RADIOPHARMACEUTICALS BASED ON FIBROBLAST ACTIVATION PROTEIN INHIBITORS IN ONCOLOGICAL PRACTICE.
| Autor: | Dzhuzha DO; Nonprofit Organization National Cancer Institute of Ministry of Health of Ukraine, 33/43 Julia Zdanovska Str., Kyiv, 03022, Ukraine., Myasoyedov SD; Shupyk National Healthcare University of Ministry of Health of Ukraine, 9 Dorogozhytska Str., Kyiv, 04112, Ukraine. |
|---|---|
| Jazyk: | English; Ukrainian |
| Zdroj: | Problemy radiatsiinoi medytsyny ta radiobiolohii [Probl Radiac Med Radiobiol] 2023 Dec; Vol. 28, pp. 49-64. |
| DOI: | 10.33145/2304-8336-2023-28-49-64 |
| Abstrakt: | The review is devoted to the application of the new perspective class of radionuclide tracers, based on inhibitors of the fibroblast activation protein (FAP), which is a marker of cancer-associated fibroblasts of microenvironment of most malignant tumors. FAP inhibitors (FAPI) can be labeled by a wide spectrum of radionuclides, which can provide both radionuclide diagnostics and radionuclide therapy. It was showed, that the diagnostic efficacy of FAPI positron emission tomography/computed tomography (PET/CT) in various cancers is similar to 18F-fluorodesoxyglu-cose-PET/CT or superior. The FAPI radiopharmaceuticals (RP) have some advantage compared to 18F-fluorodesoxy-glucose (FDG): no need for special preparation and diet, fast imaging with high contrast, and increased sensitivity in region with high glucose metabolism. FAPI-PET/CT may be an important addition to conventional methods in all stages of diagnostic process in oncology, especially when 18F-FDG cannot be used. It is need to further wide prospective investigations for assessing of diagnostic efficacy of FAPI-RP and determination of indications for its using. (D. O. Dzhuzha, S. D. Myasoyedov.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|